Pub Date : 2025-12-09DOI: 10.1016/j.ad.2025.104533
L.S. Costa , B. Obere , J. Tiscornia
{"title":"Unexpected End of a Hypochromic Macule","authors":"L.S. Costa , B. Obere , J. Tiscornia","doi":"10.1016/j.ad.2025.104533","DOIUrl":"10.1016/j.ad.2025.104533","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 3","pages":"Article 104533"},"PeriodicalIF":2.8,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145740458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-09DOI: 10.1016/j.ad.2025.104529
A. Ferreirinha , P.M. Garrido , C. Moura
{"title":"Eruptive Verrucous Keratoses and Melanocytic Nevi Induced by Encorafenib Plus Cetuximab in a Patient With Metastatic Colorectal Cancer","authors":"A. Ferreirinha , P.M. Garrido , C. Moura","doi":"10.1016/j.ad.2025.104529","DOIUrl":"10.1016/j.ad.2025.104529","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 3","pages":"Article 104529"},"PeriodicalIF":2.8,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145740212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-08DOI: 10.1016/j.ad.2025.104543
J.L. López Estebaranz , G. Segurado Miravalles , S. Ros Abarca
Vitiligo is a chronic autoimmune disease of multifactorial nature that causes skin depigmentation as a consequence of melanocyte loss. Although sometimes it is said to be untreatable, there are therapies that have succeeded in halting its progression and promoting repigmentation. One of these are inhibitors of the JAK-STAT pathway, which plays a prominent role in the immunopathogenesis of the disease. Ruxolitinib, a JAK 1/2 inhibitor, has been the first topical drug approved for the treatment of vitiligo. This narrative review addresses the immunopathologic processes involved in vitiligo, the role of the JAK-STAT pathway, and the efficacy and safety results of ruxolitinib in the treatment of nonsegmental vitiligo in adult and adolescent patients older than 12 years with facial involvement. In addition, the psychological repercussions and the impact on the quality of life suffered by patients with vitiligo are described.
{"title":"Ruxolitinib in the Treatment of Vitiligo. The Importance of the JAK STAT Pathway","authors":"J.L. López Estebaranz , G. Segurado Miravalles , S. Ros Abarca","doi":"10.1016/j.ad.2025.104543","DOIUrl":"10.1016/j.ad.2025.104543","url":null,"abstract":"<div><div>Vitiligo is a chronic autoimmune disease of multifactorial nature that causes skin depigmentation as a consequence of melanocyte loss. Although sometimes it is said to be untreatable, there are therapies that have succeeded in halting its progression and promoting repigmentation. One of these are inhibitors of the JAK-STAT pathway, which plays a prominent role in the immunopathogenesis of the disease. Ruxolitinib, a JAK 1/2 inhibitor, has been the first topical drug approved for the treatment of vitiligo. This narrative review addresses the immunopathologic processes involved in vitiligo, the role of the JAK-STAT pathway, and the efficacy and safety results of ruxolitinib in the treatment of nonsegmental vitiligo in adult and adolescent patients older than 12 years with facial involvement. In addition, the psychological repercussions and the impact on the quality of life suffered by patients with vitiligo are described.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 3","pages":"Article 104543"},"PeriodicalIF":2.8,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145720011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-08DOI: 10.1016/j.ad.2025.104540
C. Laso-Leizcano , A. Gavillero , L. Navarro-Campoamor , T. García-Lozano , E. Nagore
Background
Chemotherapy can cause multiple dermatological alterations, including nail changes that significantly impact patients’ quality of life. This study aims to characterize the nail alterations induced by chemotherapy and assess their diagnosis through dermatoscopy.
Methodology
An observational, prospective, and descriptive study that included 140 patients from the Fundación Instituto Valenciano de Oncología (FIVO). Both clinical and dermatoscopic nail alterations in the hands and feet were evaluated, associated with the different chemotherapy drugs administered. Analyzed variables included the type of nail alteration, the treatment cycle in which they appeared, and the observed dermatoscopic patterns.
Results
The prevalence of nail alterations was 45.7%, with chromonychia being the most frequent, followed by onycholysis. Lesions affected both hands and feet in 72.3% of cases. The most common chromonichias were erythronychia (36.4%) and leukonychia (9.3%). Monoclonal antibodies, tubulin binders, and platinum complexes were the drug groups most associated with these alterations. Onychomycosis was suspected in eight patients, confirmed in four cases through mycological cultures, where non-dermatophyte fungi were isolated.
Conclusion
Nail alterations induced by chemotherapy are common, affecting nearly half of patients. Dermatoscopy allowed the identification of alterations at early stages, which can facilitate the implementation of timely therapeutic strategies and improve patients’ quality of life.
{"title":"Dermatoscopic Findings of Adverse Nail Effects in Cancer Patients: Observational Study of 140 Patients","authors":"C. Laso-Leizcano , A. Gavillero , L. Navarro-Campoamor , T. García-Lozano , E. Nagore","doi":"10.1016/j.ad.2025.104540","DOIUrl":"10.1016/j.ad.2025.104540","url":null,"abstract":"<div><h3>Background</h3><div>Chemotherapy can cause multiple dermatological alterations, including nail changes that significantly impact patients’ quality of life. This study aims to characterize the nail alterations induced by chemotherapy and assess their diagnosis through dermatoscopy.</div></div><div><h3>Methodology</h3><div>An observational, prospective, and descriptive study that included 140 patients from the Fundación Instituto Valenciano de Oncología (FIVO). Both clinical and dermatoscopic nail alterations in the hands and feet were evaluated, associated with the different chemotherapy drugs administered. Analyzed variables included the type of nail alteration, the treatment cycle in which they appeared, and the observed dermatoscopic patterns.</div></div><div><h3>Results</h3><div>The prevalence of nail alterations was 45.7%, with chromonychia being the most frequent, followed by onycholysis. Lesions affected both hands and feet in 72.3% of cases. The most common chromonichias were erythronychia (36.4%) and leukonychia (9.3%). Monoclonal antibodies, tubulin binders, and platinum complexes were the drug groups most associated with these alterations. Onychomycosis was suspected in eight patients, confirmed in four cases through mycological cultures, where non-dermatophyte fungi were isolated.</div></div><div><h3>Conclusion</h3><div>Nail alterations induced by chemotherapy are common, affecting nearly half of patients. Dermatoscopy allowed the identification of alterations at early stages, which can facilitate the implementation of timely therapeutic strategies and improve patients’ quality of life.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 3","pages":"Article 104540"},"PeriodicalIF":2.8,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145720081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-08DOI: 10.1016/j.ad.2025.104544
L. Puig , J.M. Carrascosa , R. Rivera , E. Vilarrasa , P. de la Cueva , A. López-Ferrer
Generalized pustular psoriasis (GPP) is an autoinflammatory disease characterized by primarily sterile pustules, with a widespread distribution, and flares that can be associated with life-threatening complications. Spesolimab (Spevigo®) is the only drug approved for treatment and prevention of GPP flares, and there are uncertainties that justify the development by the Psoriasis Group (GPs) of the Spanish Academy of Dermatology and Venereology (AEDV) of a Delphi consensus on the diagnosis and treatment of this rare disease. A panel of experts, starting from a literature search in PubMed (since 2014), designed a structured questionnaire with assertions that were evaluated (Likert scale from 1 to 7) by 38 members of the PWG with experience in GPP. Following two rounds, between October 2024 and January 2025, agreement (≥80% of participants) was reached on 50 out of 70 statements, including the definition of GPP outbreak, infection screening, medium- and long-term treatment goals, and criteria for initiation of maintenance treatment. This Delphi consensus is intended to support clinicians in the diagnosis and treatment of patients with PPG in our setting.
{"title":"Generalized Pustular Psoriasis: Review and Consensus of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology","authors":"L. Puig , J.M. Carrascosa , R. Rivera , E. Vilarrasa , P. de la Cueva , A. López-Ferrer","doi":"10.1016/j.ad.2025.104544","DOIUrl":"10.1016/j.ad.2025.104544","url":null,"abstract":"<div><div>Generalized pustular psoriasis (GPP) is an autoinflammatory disease characterized by primarily sterile pustules, with a widespread distribution, and flares that can be associated with life-threatening complications. Spesolimab (Spevigo®) is the only drug approved for treatment and prevention of GPP flares, and there are uncertainties that justify the development by the Psoriasis Group (GPs) of the Spanish Academy of Dermatology and Venereology (AEDV) of a Delphi consensus on the diagnosis and treatment of this rare disease. A panel of experts, starting from a literature search in PubMed (since 2014), designed a structured questionnaire with assertions that were evaluated (Likert scale from 1 to 7) by 38 members of the PWG with experience in GPP. Following two rounds, between October 2024 and January 2025, agreement (≥80% of participants) was reached on 50 out of 70 statements, including the definition of GPP outbreak, infection screening, medium- and long-term treatment goals, and criteria for initiation of maintenance treatment. This Delphi consensus is intended to support clinicians in the diagnosis and treatment of patients with PPG in our setting.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 3","pages":"Article 104544"},"PeriodicalIF":2.8,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145720055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号